Univercells CEO promises 'biologics for all'

Since the inception of the biopharmaceutical age in the 1980s, the share of the market held by large molecules has risen steadily to about a fifth, and growth in the sector continues inexorably at around 7.5%.

This wave of innovation has brought enormous benefits to patients, and enormous challenges in manufacturing and distribution. Industrial-scale production of biologics demands high levels of expertise and sophistication, at great cost.

Gosselies, Belgium-based startup Univercells and chief executive Hugues Bultot believe they can help solve this problem with a unique “micro-facility,” which “can be used for different types of vaccine and other cell lines.”